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ABSTRACT
Extensive loss of dopaminergic neurons and aggregation of the
protein α-synuclein into ubiquitin-positive Lewy bodies represents a
major neuropathological hallmark of Parkinson’s disease (PD). At
present, the generation of large nuclear-associated Lewy bodies from
endogenous wild-type α-synuclein, translationally regulated under its
own promoter in human cell culture models, requires costly and time-
consuming protocols. Here, we demonstrate that fully differentiated
human SH-SY5Y neuroblastoma cells grown in three-dimensional
cell culture develop Lewy-body-like pathology upon exposure to
exogenous α-synuclein species. In contrast to most cell- and rodent-
based PD models, which exhibit multiple diffuse α-synuclein
aggregates throughout the cytoplasm, a single large nuclear
inclusion that is immunopositive for α-synuclein and ubiquitin is
rapidly obtained in our model. This was achieved without the need for
overexpression of α-synuclein or genetic modification of the cell line.
However, phosphorylation of α-synuclein within these inclusions was
not observed. The system described here provides an ideal tool to
screen compounds to therapeutically intervene in Lewy body
formation, and to investigate the mechanisms involved in disease
progression in synucleinopathies.
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INTRODUCTION
The presence of large cell-associated protein aggregates is the key
pathological hallmark commonly associated with many
neurodegenerative disorders (Poewe et al., 2017). In Parkinson’s
disease (PD) and other synucleinopathies, the intrinsically
disordered protein α-synuclein (α-syn) undergoes misfolding into
amyloid fibrils (Poewe et al., 2017). These fibrils form the major
protein component of intracellular deposits associated with Lewy
bodies (LBs) in the cell soma, and Lewy neurites (LNs) in axons of
surviving neurons (Theillet et al., 2016; Spillantini et al., 1997;
Langston et al., 2015). The association of α-syn with pre-synaptic
terminals from in vitro and in vivo models suggests a normal
physiological role in the regulation of neurotransmitter release and
synaptic function, but its role in disease remains poorly understood
(Iwai et al., 1995; Kahle et al., 2000; Murphy et al., 2000; Nemani
et al., 2010). Familial early-onset forms of PD are associated with
mutations in the SNCA gene, encoding α-syn (Polymeropoulos
et al., 1997; Singleton et al., 2003). Genomic duplications,
triplications and missense mutations (e.g. A53T, A30P, E46K and
H50Q) all implicate α-syn in the pathogenesis of PD (Spatola and
Wider, 2014). However, only 10% of cases are linked to a genetic
basis of the disease, with the majority of cases having an unknown
aetiology (Mcculloch et al., 2008; Wirdefeldt et al., 2011). Insights
from in vitro and in vivo models suggest that α-syn acts as a ‘prion-
like’ protein, with a propensity to misfold and form aggregates that
promote cell-to-cell propagation, which assists in the spread of
pathology (Braak et al., 2003; Li et al., 2008; Kordower et al., 2008;
Danzer et al., 2009; Aulic ́ et al., 2014; Hawkes et al., 2007).
The mechanisms underlying LB formation and the influence of
α-syn pathology on disease pathogenesis remain poorly understood,
largely due to the lack of whole-animal or cell-based models that
recapitulate the development of these inclusions. One of the
significant barriers in PD research surrounds the difficulty in
obtaining cultures of the A9-subtype dopaminergic neuronal
population that are specifically affected in the disease (Arenas
et al., 2015). Several cell culture models have been used for studying
PD, and to investigate the role of α-syn aggregation. These models
include: non-patient-specific human cell lines (SH-SY5Y,
HEK293, LUHMES); animal-derived cell lines (rat PC12, mouse
N2a cells); stem cells, including induced pluripotent cell lines
(iPSCs) and human mesenchymal (MSCs)/embryonic stem cells
(ESCs); and primary animal-derived midbrain neuron cultures
(Falkenburger et al., 2016; Smidt and Burbach, 2007). Each of these
cell types has its own strengths and limitations; for example, the use
of iPSCs that differentiate into dopaminergic neurons in vitro
overcomes the ethical issues associated with using ESCs. However,
culturing these cells is expensive and labour-intensive (as long as
75 days in culture), meaning that their use is inevitably out of reach
for many research groups (Smirnova et al., 2016; D’Antonio et al.,
2017). The cost incurred, time constraints and ethical framework
required for animal-based research are again inhibitory for many
laboratories.
To address the experimental and ethical issues of ESCs and animal
models, alternative systems have been developed to model the
complex pathogenesis of the disorder. Relatively few studies have
observed the development of LB pathology without overexpressing
high levels of human versions of α-syn (Volpicelli-Daley et al., 2011;
Falkenburger et al., 2016). In addition, a predominant number of
studies rely on the introduction of a familial mutation into α-syn (e.g.
A53T) to increase aggregation propensity (Li et al., 2001; Koprich
et al., 2017). Recombinant expression of wild-type (WT) humanReceived 11 November 2018; Accepted 21 March 2019
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α-syn in Drosophila mirrors the formation of LB-like structures and
neuronal loss, but this has unfortunately not been replicated in higher-
order organisms or human-cell-based models (Feany and Bender,
2000). Interestingly, rodent models of PD that overexpress human
α-syn by mutations in the SNCA gene (e.g. the M83 strain,
overexpressing mutant human A53T α-syn) do develop inclusions
but the anatomical distribution is widely variable among animals and
often coincides with areas of substantial neuroinflammation (Sacino
et al., 2014; Lee et al., 2002; Dawson et al., 2011; Fares et al., 2016).
Importantly, impaired human α-syn fibrillisation can occur in rodent
models due to an interaction with endogenously expressed mouse
α-syn. Such interactions highlight a fundamental experimental caveat
when investigating LB formation in mouse models or rodent-derived
primary neuronal cultures (Fares et al., 2016). Species differences
between rodent models (including primary rodent cell culture
systems) make it difficult to model and extrapolate findings to
human subjects (Goldie et al., 2014; Ioannidis, 2012; Pound and
Bracken, 2014).
In previous human-cell-based models, limitations have also arisen
from the use of traditional two-dimensional (2D) monolayers.
Intracellular α-syn aggregates are often observed as multiple
cytoplasmic punctate inclusions rather than recapitulating the
typical large singular inclusions associated with human pathology
(Danzer et al., 2009; Desplats et al., 2009; Aulic ́ et al., 2014).
Formation of LB-like pathology in human cell culture models has
only been achieved through overexpression of α-syn, either driven
from viral promoters or in cell lines not associated with the disease,
such as those from human embryonic kidney lines (HEK-293)
(Volpicelli-Daley et al., 2011; Luk et al., 2009; Sacino et al., 2013).
Such viral promotors do not allow the study of transcriptional and
translational modulations brought about during the disease state. To
address these issues, in vitro 3D culture systems are increasingly
being utilised for a multitude of disease models, with the aim of more
closely mimicking an in vivo environment with tissue-like cell
density and cell-to-cell as well as cell-to-extracellular-matrix contacts
(Griffith and Swartz, 2006; Tang-Schomer et al., 2014; Choi et al.,
2014; Smirnova et al., 2016). Taken together, the limitations of both
in vitro and in vivo models demonstrate a greater need to develop a
human-relevant culture system to model LB pathology.
The use of human-derived neuroblastoma cell lines, such as the
SH-SY5Y catecholaminergic neuroblastoma cell line, remains a
popular choice in PD research (Xicoy et al., 2017). Although the
SH-SY5Y cell line does display genetic anomalies, it is important to
note that nearly all pathways dysregulated in PD remain intact in this
line (Krishna et al., 2014) and punctate intracellular inclusions can
be induced by exposure to preformed amyloid material (Illes-Toth
et al., 2015). In addition, upon differentiation, this proliferative
immature neuroblast expresses the characteristic proteins associated
with dopaminergic neurons, including tyrosine hydroxylase (TH)
and dopamine transporter (DAT), making it a comparable model of
the cell type affected in the disease state (Presgraves et al., 2004;
Lopes et al., 2010; Kovalevich and Langford, 2013).
Differentiation to a fully mature neuronal phenotype can be
achieved using all-trans retinoic acid (RA), followed by treatment
with brain-derived neurotrophic factor (BDNF) (Encinas et al.,
2000). This procedure yields a preferentially homogenous
population of cells compared to other differentiation protocols,
including short- or long-term treatment with RA alone (Encinas
et al., 2000). Although the importance of using differentiated SH-
SY5Y in PD research is becoming increasingly apparent, a large
number of publications still either use the undifferentiated line, do
not report their differentiation protocol or employ a differentiation
protocol that solely utilises RA. These procedures then do not fully
provide a mature neuronal phenotype (Goldie et al., 2014; Xicoy
et al., 2017).
Here, we developed an easily replicable cell culture methodology
that recapitulates the formation of LB-like inclusions. The Encinas
et al. (2000) protocol was adapted to generate neuron-like cells in a
2D cell culture format that could subsequently be maintained within
a 3D matrix. By incorporating the RA+BDNF-differentiated cells
into a 3D matrix, we have been able to induce the formation of
nuclear-associated ubiquitinated LB-like α-syn aggregates upon
treatment with preformed α-syn oligomers. The formation of
these LB-like aggregates was achieved without the need for
overexpression of α-syn or modification of the genomic material.
RESULTS
Differentiated SH-SY5Y in 2D culture express markers
of dopaminergic neurons
Controversy remains as to whether RA or RA+BDNF promotes
SH-SY5Y cell differentiation and the development of a terminal
neural dopaminergic phenotype (Korecka et al., 2013; Xicoy et al.,
2017; Lopes et al., 2010). Thus, transcriptional and translational
analysis of key neuronal markers was carried out to
limit assumptions regarding the phenotypic state of the SH-SY5Y
cell line used here. Undifferentiated SH-SY5Y cells display a
characteristic morphology of two distinct phenotypes: neuroblastic
(‘N-type’; Fig. 1A, arrow); and substrate adherent (‘S-type’;
Fig. 1A, asterisk). In agreement with others (Korecka et al., 2013;
Forster et al., 2015; Ito et al., 2017), upon treatment with RA or
RA+BDNF, the neuroblastic SH-SY5Y cells differentiated to a
more neuron-like phenotype. Average neurite lengths and standard
deviations of 51.22±22.87 µm (undifferentiated), 64.91±33.07 µm
(RA) and 130.50±77.91 µm (RA+BDNF) were observed (Fig. 1A),
with interquartile ranges of 34.43-62.53, 40.83-80.85 and 74.83-
164.8 µm, respectively. Significantly longer neurite length was
observed in both RA and RA+BDNF groups compared to
undifferentiated cells, with increased network complexity in the
RA+BDNF group (Fig. 1A). Following treatment with RA, the non-
differentiating ‘S-type’ population was increasingly visible at day 5
and, if continuously cultured up to 14 days, under these conditions,
progressively overgrew the cultures (data not shown). The addition
of BDNF and withdrawal of RA promoted the development of a
homogenous population of cells with a negligible amount of
‘S-type’ cells surviving (Encinas et al., 2000).
Key to the development of an effective cell culture model of PD is
the expression of relevant neuronal markers. Cells at all stages of
differentiation were stained with antibodies for the neuron markers
neurofilament 200 (NF200) (Fig. 1B) and βIII-tubulin (encoded by
TUBB3) (data not shown). NF200 staining was reduced following
differentiation with RA (7±3%) compared to undifferentiated
SH-SY5Y (43±21%), potentially relating to an increased
population of ‘S-type’ cells within the culture. NF200
immunopositivity was increased in RA+BDNF (64±17%)
compared to undifferentiated and RA groups. Ki67 is a protein
associated with cell proliferation that is present in the G1, S and G2
phases of cell cycling and mitosis but absent in the G0 resting state.
Undifferentiated neuroblastoma cultures expressed this marker
[591,943±171,477 corrected total cell fluorescence (CTCF)/cell].
A significant reduction in expression seen in the RA (193,629±
160,908 CTCF/cell) and RA+BDNF (180,465±105,445 CTCF/
cell) cells indicate that they are terminally differentiated (Fig. 1C).
Tyrosine hydroxylase (TH) is a key enzyme in the production and
homeostasis of dopamine (DA) within catecholamine neuronal cell
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Fig. 1. Characterisation of SH-SY5Y cells following differentiation with RA alone or sequential treatment with RA+BDNF. (A) Representative phase-
contrast images of SH-SY5Y differentiated with RA alone and sequential treatment with RA+BDNF. Neurite length measurements were determined bymeasuring
200 neurites per treatment group, with three independent biological repeats. All data points are presented, with the mean shown as a straight line. Neuroblastic
(‘N-type’; arrow) and substrate adherent (‘S-type’; asterisk) cells are shown. (B-D) Immunocytochemistry analysis of differentiated cultures stained for NF200,
Ki67 and dopamine (DA) (red). Nuclei were visualised using DAPI staining (blue). Individual data points presented with mean (straight line) for% immunopositivity
(B) and CTCF/cell data (C,D) of three independent biological repeats. (E) mRNA levels of genes specifically associated with dopaminergic neurons were
evaluated by qPCR. Undifferentiated cells (blue), RA treatment group (red) and RA+BDNF treatment group (green). Relative gene expression normalised to
reference genes (ACTB and YWHAZ) and undifferentiated SH-SY5Y. Neuronal (TUBB3 and MAP2) and dopaminergic (DAT, DRD2 and VMAT2) markers
showed increased expression in the RA+BDNF group (green) relative to the undifferentiated cells (blue). Immature neuronal marker (NES) expression was not
significantly changed following differentiation with RA or RA+BDNF. Data presented asmean±s.e.m. of at least three independent experiments. (A-E) Differences
between treatments were tested for significance using the Kruskal–Wallis test with post hoc Dwass-Steel-Chritchlow-Fligner for >6 data points and Conover-
Inman for <6 data points. P-values are displayed in the figures. Scale bars: 100 µm (A); 50 µm (B-D).
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types (Daubner et al., 2011) and is expressed in all three cell types
(Fig. S1). An anti-DA antibody that has been demonstrated to be
specific for DA through cross-reactivity studies (Banks et al., 2017)
was used to determine the presence of this neurotransmitter. These
terminally differentiated SH-SY5Y cells were also shown to retain a
dopaminergic phenotype, whereby DA immunoreactivity was
significantly increased in RA+BDNF (21,800±7126 CTCF/cell)-
treated cultures compared to undifferentiated cells (19,884±6371
CTCF/cell) or those treated with RA (10,216±5823 CTCF/cell)
(Fig. 1D).
Evaluation of the mRNA levels after each differentiation protocol
by quantitative real-time PCR (qPCR) was used to determine the
transcriptional levels of genes specifically associated with
dopaminergic neurons (Fig. 1E). Increased expression of the
neuronal markers βIII-tubulin (TUBB3) and microtubule-
associated protein 2 (MAP2) upon RA+BDNF treatment
confirmed the development of a more neuronal phenotype than
observed with RA-treated or undifferentiated SH-SY5Y cells.
Nestin (NES), an immature neuronal marker, was not significantly
changed by differentiation with either RA alone or RA+BDNF
treatment. A greater dopaminergic phenotype in RA-BDNF
differentiated cultures was observed, indicated by elevated
expression levels of DAT, DA receptor D2 and vesicular
monoamine transporter member 2 when compared to the other
two cell populations (Fig. 1E). Overall, these observations are in
linewith previously published work on differentiated SH-SY5Y cell
lines in which RA+BDNF treatment was utilised, and demonstrate
that these conditions result in terminally differentiated cells
expressing many of the key markers of a dopaminergic neuron
(Ito et al., 2017; Agholme et al., 2010; Xicoy et al., 2017).
Exogenous α-syn oligomers induce intracellular aggregation
Within the PD brain, LB pathology is only observed in a discrete
cell population within ex vivomaterial (Braak et al., 2003). Here, we
wanted to determine whether the extent of cellular differentiation
resulted in alterations in the intracellular aggregation propensity of
the cell line. Previous studies by us and others have shown that a
distinct subtype of soluble oligomeric α-syn can seed intracellular
aggregation of endogenous α-syn in undifferentiated SH-SY5Y
lines (Danzer et al., 2009; Illes-Toth et al., 2015). Following
addition of oligomeric α-syn to undifferentiated SH-SY5Y cells, the
presence of multiple punctate α-syn-positive cytoplasmic inclusions
with an average inclusion size of 0.28 µm2 was confirmed in our
model (Fig. 2A,B). The addition of the same oligomer treatment on
RA-differentiated cultures also produced several small cytoplasmic
inclusions within each cell, but the average inclusion size was
significantly larger (0.82 µm2) than in the undifferentiated
SH-SY5Y cells (Fig. 2A,B). In both undifferentiated and
RA-differentiated SH-SY5Y cells, all surviving cells developed
the punctate inclusions (Fig. 2C).
In contrast, the addition of the same soluble oligomeric α-syn
preparation to RA+BDNF-differentiated culture media
demonstrated the development of a single perinuclear inclusion,
consistent with a large LB-like aggregate (Fig. 2A, asterisks and
arrows), with an average inclusion size of 8.95 µm2. Cellular
inclusions could be detected 24 h after treatment, but only 31% of
Fig. 2. Exogenous addition of α-syn oligomers induces the intracellular aggregation of α-syn in 2D SH-SY5Y cultures. (A) Double immunostaining of
undifferentiated and differentiated SH-SY5Y cells reveals intracellular aggregation of α-syn following 24 h incubation with seeding oligomers. α-Syn inclusions in
undifferentiated cells display several distinct, punctate accumulations dispersed throughout the cytoplasm, consistent with aggregates. In contrast, the RA+BDNF
cell lines show a single prominent accumulation (red; arrows) and obscure the nucleus (asterisks). Scale bars: 50 µm. (B) Quantification of inclusion area
(reflected as µm2) shows inclusions that are present in differentiated cells to be much larger than those in undifferentiated cells (measurements obtained from
three independent experiments; n=50). All data points are present, with mean shown as a straight line. (C) The percentage of cells containing inclusions was
determined by counting 100 cells per repeat. Cells were deemed to contain inclusions if aggregation matched that in reference images when compared to
controls. Data points are presented from three independent biological repeats. (B,C) Differences between treatments were tested for significance using Kruskal–
Wallis test with post-hoc Dwass-Steel-Chritchlow-Fligner for >6 data points and Conover-Inman for <6 data points. P-values are displayed in the figures.
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the cell population developed these structures (Fig. 2C). To our
knowledge, this is the first observation of single large inclusions
within a genetically unmodified cell culture model.
SH-SY5Y differentiation in 3D culture retains a dopaminergic
phenotype
Despite the promising initial phenotypic outcomes from the
RA+BDNF-differentiated cells cultured in a 2D format, the protocol
was not robust. These cells tended to detach from the culture vessel
before the end of BDNF treatment and as such presented a wide
variation in inclusion size (Fig. 2B) and viability (Fig. S2A). This
detachment from the culture vessel meant that, although images could
be produced of cells containing LB-like inclusions, the experiment
itself was not repeatable enough for future investigations. We,
therefore, sought to adapt our culturing procedure to allow for greater
retention of cells after RA+BDNF differentiation. It was hoped that
differentiation of these cells in a 3D matrix would stabilise the cell
population during the development of LB-like inclusions and allow
more robust handling methods during processing and analysis.
A variety of cell densities were used to evaluate the optimal cell
conditions for differentiation in 3D. In 300 µl matrix volumes (in
24-well inserts), incremental increases in densities from 1×106 cells/
ml to 1.25×107 cells/ml steadily decreased the viability of cells
within the matrix (∼17%) as measured by lactate dehydrogenase
(LDH) concentration (Fig. 3A). Upon differentiation in the 3D
matrix, gene expression of DRD2, MAP2 and VMAT2 were
increased (compared to undifferentiated SH-SY5Y) (Fig. 3B). A
substantial increase in VMAT2 expression within the same cells
differentiated in 3D compared to 2D indicated the development of a
more neuronal phenotype.
Based on these observations, a cell density of 7.5×106 cells/ml
was selected for further studies. At this cell density, the expression
levels of DAT, DRD2, MAP2, TUBB3 and VMAT2 were all
increased in relative abundance to the undifferentiated cells, and
NES expression was decreased in comparison to other cell densities.
Cells displayed a homogenous distribution within the matrix, in
contrast to lower densities where clusters of cells were observed
(Fig. S2B). In addition, this was the highest cell density at which cell
viability was unaffected. Hence, 7.5×106 cells/ml was the optimal
balance between viability and homogeneity within the matrix. To
demonstrate comparable differentiation of SH-SY5Y cultures after
7 days of treatment with RA+BDNF in 2D or 3D, all cells were
confirmed to be immunonegative for Ki67 and immunopositive for
NF200 and DA (Fig. 3C).
Fig. 3. Neuron-like cells cultured in 3D retain a dopaminergic phenotype. (A) Cell number optimisation of 3D-differentiated SH-SY5Y using LDH cell viability
assay. An incremental increase in cell density is associated with decreased cell viability (∼17% decrease from 1×106 cells/ml to 1.25×107 cells/ml). LDH cell
viability assay was normalised to cell-density-matched positive controls. All data points are present, with mean shown as a straight line of at least four independent
repeats. (B) mRNA levels of genes specifically associated with dopaminergic neurons were evaluated by qPCR in different cell densities. Relative gene
expression normalised to reference genes (ACTB and YWHAZ) and undifferentiated SH-SY5Y. Expression of neuronal (TUBB3, MAP2 and NES) and
dopaminergic (DAT, DRD2 and VMAT2) markers was evaluated in cell densities. A density of 7.5×106 cells/ml demonstrated increased expression of DRD2,
MAP2 andVMAT2, and was chosen for further experiments. Data presented asmean±s.e.m. of at least three independent experiments. (C) 3D-differentiated SH-
SY5Y cultures retain a post-mitotic neuronal dopaminergic phenotype in 3D as determined by the absence of Ki67 staining and positive staining for NF200 and
dopamine. Positive control for Ki67 staining is undifferentiated SH-SY5Y cultured in 3D. Scale bars: 100 µm.
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Seeded inclusions in 3D cultures are reminiscent of human
Lewy bodies
In vivo LBs are phenotypically more complex than the punctate
aggregates of α-syn seen in 2D cell culture models. To determine the
morphological changes in intracellular aggregates in 3D culture, fully
differentiated cells within the matrix were treated with preformed
α-syn oligomers. Similar to our observations in 2D cultures (Fig. 2),
inclusions in our 3D cell culture model were detectable 24 h after
α-syn oligomer treatment (Figs 4 and 5). Immunostaining of these
nuclear-associated inclusions in our 3D model confirmed that they
were α-syn positive (Fig. 4A) and an equivalent size to those seen
in vivo (Fig. 5A). Fig. 4B shows the percentage of α-syn
immunopositivity in 3D cultures treated for 24 h with media,
solvent or α-syn in monomeric or oligomeric preparations. The
data demonstrate that oligomer-treated cells develop significantly
more inclusions than control cells. The percentage of cells containing
observable inclusions also significantly increased relative to controls
(Fig. 4C). Immunostaining for ubiquitin in the oligomer-treated 3D
cell cultures demonstrated diffuse nuclear-associated staining that
colocalised with the LB-like aggregates (Fig. 5B). Co-staining
using both anti-α-syn and anti-ubiquitin antibodies demonstrates
colocalisation of both proteins within the same inclusion (Fig. 5C).
These inclusions are highly reminiscent of in vivo material
(Shults, 2006), and completely absent in the isotype controls and
untreated cultures (Fig. S3). Immunohistochemical detection of
phosphorylated α-syn at S129 using a selective antibody was not able
to show evidence of phosphorylation following 24 h treatment. This
would indicate that the aggregates have either formed without the
requirement for phosphorylation or that the S129 epitope is protected
within these aggregates (Walker et al., 2013). The lack of observable
phosphorylation within the inclusions would suggest that this
post-translational modification may not be required for aggregate
formation within this model, or occurs within a timeframe exceeding
that used here. If so, then the LB-like inclusions observed here could
represent an early aggregated morphology. Overall, the 3D
differentiated SH-SY5Y culture model presented here can produce
LB-like aggregates when treated with preformed oligomeric material
that recapitulates characteristic in vivo LB.
DISCUSSION
Previously, our group (Illes-Toth et al., 2015) and others (Danzer
et al., 2007, 2009) have reported the induction of punctate
Fig. 4. Exogenous α-syn oligomers seed the development of intracellular inclusions in 3D SH-SY5Y cultures. (A) Representative images of α-syn staining
with syn211 monoclonal antibody (brown) with nuclei visualised using DAPI staining (blue/purple). α-syn oligomer treatment to cells leads to strong
immunoreactivity for α-syn compared to isotype controls (Fig. S2), media only, or treatment with solvent or α-syn monomer. Arrows indicate the location of the
intracellular inclusions. Scale bars: 100 µm. (B) Percentage of α-syn immunopositivity in 3D cultures treated for 24 h with media, solvent or α-syn in monomeric
or oligomeric preparations. Cells were deemed to contain inclusions if aggregation matched that in reference images when compared to controls. Data presented
as mean±s.e.m. of three independent experiments. (C) Monomeric and oligomeric α-syn treatments resulted in an increase in the percentage of cells with
inclusions. Statistical significance in the oligomer-treated cultures related to the increase in large inclusions compared with media and solvent controls. Data
presented as mean±s.e.m. of three independent experiments. (*, compared to media; •, compared to solvent). Evaluation of immunohistochemical staining was
performed by counting 200 cells per slide, with ten slides counted per repeat (2000 cells counted in each treatment group for three independent experiments).
(B,C) Statistical differences were determined using the Kruskal–Wallis test with post hoc Conover-Inman (*/•P≤0.05, **/••P≤0.01).
6
RESOURCE ARTICLE Disease Models & Mechanisms (2019) 12, dmm038042. doi:10.1242/dmm.038042
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
intracellular aggregates in 2D undifferentiated cells when specific
preparations of oligomeric α-syn are added to the media. Findings
presented here describe a human 3D cell culture model that
recapitulates LB-like formation. Inclusions are initiated by
oligomeric α-syn preparations when introduced to terminally
differentiated post-mitotic, neuron-like SH-SY5Y cells within a
3D matrix. Elevated expression of TUBB3 and MAP2 upon
differentiation indicated stronger neuronal characteristics than
when undifferentiated, and the detection of DAT, DRD2 and DA
confirmed a dopaminergic phenotype. Importantly, although the
LB-like structures present in our model do not show evidence of
phosphorylation, they are positive for α-syn and ubiquitin, closely
resembling the morphology of inclusions found within the human
pathology (Goedert et al., 2013).
Certain forms of α-syn located in the extracellular environment
have recently been shown to be internalised by neurons through
several receptor-mediated mechanisms and induce self-aggregation
of endogenous α-syn (Bieri et al., 2018). The oligomers used in this
study have previously been shown to induce the intracellular
aggregation of α-syn by providing a nucleation site that recruits
endogenous α-syn in the development of cell-associated aggregates
(Danzer et al., 2009). This prion-like propagation has been proposed
to explain the spread of the disease through the neuronal network
and justify the post-mortem observations of α-syn aggregates in a
PD patient that had undergone midbrain embryonic neuronal
transplants (Braak et al., 2003; Kordower et al., 2008). Following
internalisation, the ability of α-syn to trigger oligomerisation of
endogenous α-syn potentially occurs through the oxidative or other
stress responses (Deas et al., 2016; Di Maio et al., 2016). Although
the precise series of events surrounding the development of these
inclusions remains to be established, a model system such as the
one described here opens the opportunity to investigate these
mechanisms within a controlled environment and without the need
to genetic modify or overexpress α-syn.
In multifactorial disorders such as PD, dissecting the complex
pathological processes into simpler molecular events may allow us to
better interpret disease progression. Using the 3D cell culture model
described here may allow us to identify therapeutic interventions and
the pathways leading to LB development before translating them to
more complex models of the brain (e.g. transgenic mouse models) in
which confounders such as neuroinflammation and innate immunity
could mask the pathways required to be studied.
MATERIALS AND METHODS
Expression and purification of recombinant wild-type α-syn
HumanWT α-syn was prepared as described previously (Smith et al., 2008).
Briefly, α-syn was expressed in Escherichia coli BL21 (DE3) cells (New
England Biolabs, Ipswich, MA, USA). Expression was induced using
autoinduction media (Formedium, Norfolk, UK) at 37°C for 24 h. Bacterial
cells were harvested by centrifugation at 4°C, 10,000 g and resuspended in
lysis buffer [10 mM Tris-HCl (pH 8.0), 100 µg/ml lysozyme (Sigma-
Aldrich, Poole, UK), 1 mM phenylmethylsulphonyl fluoride (PMSF;
Sigma-Aldrich), 20 µg/ml DNase (Sigma-Aldrich), 20 µg/ml RNase
(Sigma-Aldrich) and protease inhibitor cocktail (Life Technologies,
Paisley, UK)]. The protein pellet was subjected to anion exchange
followed by size exclusion chromatography. Lyophilised purified α-syn
was stored at −20°C. Protein concentration was measured using a UV/vis
spectrophotometer (CECIL 1000) at absorbance 280 nm with an extinction
coefficient of 5960 M−1 cm−1.
Preparation of seeding oligomers
Seeding oligomers were prepared as previously described by Danzer et al.
(2009), omitting the addition of 10 µM FeCl2. Briefly, lyophilised α-syn
was dissolved in 50 mM sodium phosphate buffer (pH 7.0) containing 20%
ethanol to a final concentration of 7 µM. Following overnight incubation at
21°C with continuous shaking, oligomers were concentrated 1:14 using
Fig. 5. α-Syn-seeded inclusions in 3D are indicative of in vivo Lewy body inclusions. α-Syn oligomer treatments to 3D-differentiated cultures develop α-syn-
positive inclusions that demonstrate the same morphology as in vivo Lewy bodies (LBs; A) and are positive for the marker ubiquitin (B). Dotted line in purple
highlights cell nuclei, whereas brown dotted line highlights stained area. (C) Immunofluorescence shows colocalisation of α-syn (red) and ubiquitin (green)
staining. Nuclei were visualised using DAPI staining (blue). Scale bars: 50 µm (left) and 10 µm (right). In vivo pathology image displayed with permission from
Springer Nature. This image is not published under the terms of the CC-BY license of this article. For permission to reuse, please see Chesselet et al. (2012).
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ultracentrifugation (VivaSpin 500 columns, MWCO 30 kDa, GE
Healthcare, Buckinghamshire, UK), allowing the separation of oligomeric
species from monomeric protein. Each batch of oligomers was used for
experiments straight away.
Cell culture, media and reagents
SH-SY5Y human neuroblastoma cells were purchased from the European
Collection of Authenticated Cell Cultures (cat. no. 94030304; Public Health
England, Salisbury, UK). All cell lines were confirmed to be mycoplasma
free at 3-month intervals. Cell cultures were maintained at 37°C, 5% CO2
in DMEM high glucose with L-glutamine media (Lonza, Slough, UK)
supplemented with 10% (v/v) foetal bovine serum (FBS; Life Technologies)
and 1% (v/v) penicillin/streptomycin (P/S; Life Technologies); all
experiments were completed within ten passages. For treatment with
seeding oligomers, undifferentiated SH-SY5Y cells were allowed to adhere
and expand to 70% confluence before treatment with monomeric α-syn,
oligomeric α-syn or appropriate solvent controls for 24 h. For 2D
differentiation into neuronal-like cells, cells were pre-differentiated in
DMEM high glucose with L-glutamine supplemented with 10% (v/v) FBS,
1% (v/v) P/S and 10 µM all-trans-RA (Sigma-Aldrich). After 5 days in the
presence of RA, cells were washed with serum-free DMEM and media
changed to 50 ng/ml BDNF-supplemented (BDNF; cat. no. 450-02;
PeproTech, London, UK) serum-free DMEM for 7 days. Following
incubation, differentiated SH-SY5Y cells were treated with monomeric α-
syn, oligomeric α-syn or appropriate solvent controls for 24 h at 10% v/v
(0.01 mg/ml concentration referring to the monomer’s concentration) (Illes-
Toth et al., 2015; Danzer et al., 2007). Phase-contrast images of differentiated
cells were captured using an Olympus Inverted microscope. Neurite length
wasmeasured using the free open source software, ImageJ 1.50i, whereby 200
neurites per treatment were measured, in three independent experiments.
Immunofluorescence staining
For immunofluorescence staining, 2D cultures were fixed with ice-cold
methanol for 15 min at −20°C followed by washing with phosphate buffered
saline (PBS) solution containing 0.1% (v/v) Tween-20 (PBS-T; Sigma-
Aldrich). After washing, unspecific binding sites were blockedwith a solution
containing PBS and 1% (w/v) bovine serum albumin (BSA; Sigma-Aldrich)
for 1 h at room temperature under gentle continuous shaking. After blocking,
cells were washed in PBS-T before incubation with primary antibody in
blocking solution for 1 h at room temperature under gentle continuous
shaking. The following antibody dilutions were used in this study: anti-α-
synuclein (syn211; 1:2000 dilution; cat. no. 32-8100; Invitrogen,
ThermoFisher Scientific, Loughborough, UK), anti-DA (1:200; ab6427;
Abcam, Cambridge, UK), anti-hypophosphorylated NF200 (1:100; ab82259;
Abcam) and anti-Ki67 (1:200; ab16667; Abcam). Following primary-
antibody incubation, cells were washed with PBS-T and incubated with
secondary antibody [Texas Red™ goat anti-mouse IgG (H+L); cat. no.
100125662; ThermoFisher Scientific] for 1 h at room temperature in the dark.
Nuclei were counterstained with 0.1 µg/ml 4′,6-diamidino-2-phenylindole,
dihydrochloride (DAPI; Sigma-Aldrich) for 5 min. Slides were mounted with
immersion oil, sealed with nail varnish and left to cure overnight at 4°C in the
dark prior to image capture using an Olympus BX60 brightfield/fluorescence
microscope. Evaluation of immunofluorescence staining was performed by
counting 200 cells per repeat, with immunopositive cells expressed as a
percentage of total count. To quantify total fluorescence per cell, fluorescent
images were analysed using the image analysis software ImageJ 1.50i using
the CTCF calculation, in which the background fluorescence in a selected area
is subtracted from the fluorescence value of a measured area, using the
calculation: CTCF=[Integrated density−(Mean fluorescence reading of
background×Fluorescence of area of selection)]/Cell number. Three
independent biological repeats were performed in total.
3D cell culture and differentiation
Cells were pre-differentiated with RA in uncoated T75 flasks for 5 days
prior to seeding into 3D Matrigel™ cultures. Matrigel™ was diluted to
6 mg/ml total protein with ice-cold serum-free DMEM and vortexed with
cell pellets for 10 s, to a final cell concentration of approximately 7.5×106
cells per ml of diluted Matrigel™. Using pre-chilled pipettes, Matrigel™/
cell mixtures were transferred to either pre-warmed 8-well chamber slides or
tissue culture inserts (ThinCerts; 0.4 µm pore size, Greiner Bio-One,
Gloucestershire, UK), at 100 µl and 300 µl volumes, respectively, and
incubated at 37°C for 1 h to form a colloidal gel. Following solidification of
the 3D gels, pre-warmed serum-free DMEM supplemented with 50 ng/ml
BDNF was added to the cultures and cells differentiated for a further 7 days.
Media was changed every 3-4 days. After 7 days in 3D, cultures were treated
with monomeric α-syn, oligomeric α-syn or appropriate solvent controls for
24 h at 10% v/v (0.01 mg/ml concentration referring to the monomer’s
concentration) (Illes-Toth et al., 2015; Danzer et al., 2007).
Cryostat sectioning and histological staining of 3D cultures
For cryostat sectioning, 3D cultures grown in tissue inserts were frozen and
stored at −80°C before sectioning. The frozen samples were cut into 10 µm
sections (Leica CM3050 S Research Cryostat, LeicaMicrosystems, Newcastle
upon Tyne, UK) at −25°C and mounted on X-tra® adhesive glass slides
(Leica Microsystems) and stored at −80°C prior to staining. For
immunohistochemistry, 10 µm frozen sections from 3D thick-layer cultures
were fixed with ice-cold 1:1 methanol and acetone, and endogenous
peroxidases blocked. Staining with anti-α-synuclein monoclonal antibody
(syn211; 1:100 dilution; Invitrogen) was performed using the Mouse on
Mouse Polymer IHC Kit according to the manufacturer’s protocols
(ab127055; Abcam, Cambridge, UK). Staining with anti-ubiquitin (1:50
dilution; cat. no. ab7780; Abcam) rabbit primary antibodies was performed
using the following method. Following Tris-buffered saline (TBS) washes,
non-specific binding sites were blocked at room temperature for 2 h with 25%
(v/v) normal goat serum (cat. no. 11819220; ThermoFisher Scientific,
Loughborough, UK) and 1% (w/v) BSA in TBS. Sections were incubatedwith
primary antibody overnight at 4°C. Slides were washed in TBS, and a 1:500
dilution of biotinylated goat anti-rabbit secondary antibody (cat. no. ab6720;
Abcam) in 1% (w/v) BSA/TBS was applied for 30 min at room temperature.
Binding of the secondary antibody was detected using a streptavidin-biotin
complex (Vector Laboratories, Peterborough, UK) techniquewith 0.08% (v/v)
hydrogen peroxide in 0.65 mg/ml 3,3-diaminobenzidine tetrahydrochloride
(DAB; Sigma-Aldrich) in TBS. Sections were counterstained with Mayer’s
Haematoxylin (Leica Microsystems), dehydrated, cleared and mounted
with Pertex mounting medium (Leica Microsystems). Evaluation of
immunohistochemical staining was performed by counting 200 cells per
slide, with ten slides counted per repeat (2000 cells counted in each treatment
group for three independent experiments); immunopositive cell values are
expressed as a percentage of the total count.
Immunofluorescence of 3D cultures
For immunofluorescence of 3D cultures, frozen sections were fixed with 1:1
ice-cold methanol:acetone. Blocking was performed using the Mouse on
Mouse Polymer IHC Kit according to the manufacturer’s protocols
(ab127055; Abcam). Slides were incubated with anti-α-syn (syn211;
1:100 dilution; Invitrogen) and anti-ubiquitin (1:1000; cat. no. ab7780;
Abcam) primary antibodies for 1 h at room temperature. Following PBS-T
washes, secondary antibodies [Alexa Fluor® 488 goat anti-rabbit IgG (H+L)
cat. no. ab150077, Abcam, and Texas Red™ goat anti-mouse IgG (H+L)
cat. no. 100125662, ThermoFisher Scientific] were incubated at 1:1000
dilution for 1 h at room temperature. Nuclei were counterstained with
0.1 µg/ml DAPI (Sigma-Aldrich) for 5 min. Slides were mounted with
immersion oil, sealed with nail varnish and left to cure overnight at 4°C in
the dark before image capture using a Leica LSM 800 confocal microscope.
RNA extraction, cDNA synthesis and qPCR
Total RNAwas extracted using either TRIzol® Reagent (Life Technologies)
or the ReliaPrep™ RNA Cell Miniprep System (Promega, Southampton,
UK) according to the manufacturers’ protocols. Complementary DNAs
(cDNAs) were synthesised by the nanoScript 2 Reverse Transcriptase kit
(Primerdesign, Chandler’s Ford, UK) from equal amounts of purified RNA
(1 µg). Target genes were investigated using qPCR conducted on either
undifferentiated or differentiated SH-SY5Y populations using pre-validated
primer sets (Primerdesign). Reaction volumes of 20 µl were prepared using
PrecisionPLUS 2× Real-Time PCR MasterMix premixed with ROX and
SYBR green (Primerdesign). The amplification was performed under the
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following conditions: 2 min at 95°C and then 40 cycles at 95°C for 15 s and
60°C for 60 s followed by a post-PCR melt-curve analysis performed on a
StepOnePlus™ Real-Time PCR System (Applied Biosystems, Lutterworth,
UK). The sizes of PCR products were confirmed using agarose gel
electrophoresis. Reference gene analysis was undertaken using the
geNormPLUS kit (Primerdesign) and Qbase+ software (Primerdesign) to
identify inherently stable reference genes between different treatment
groups. Gene expression levels were normalised against reference genes
ACTB (β-actin) and YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta polypeptide) for each sample and
fold changes were calculated using the 2−ΔΔCt method (Schmittgen and
Livak, 2008) by setting the expression levels of each gene in
undifferentiated SH-SY5Y cells as 1. Data collected from at least three
independent biological replicates was calculated and plotted as mean log10-
fold changes ±s.e.m.
Cell viability
Cell viability of 2D or 3D cultures was analysed with either resazurin
(mitochondrial activity) or lactate dehydrogenase (LDH; cell membrane
integrity) levels. For the resazurin reduction assay, a 3 mg/ml stock solution
of resazurin was prepared in cell culture media and further diluted to 10 µg/
ml. Following treatment with oligomeric or monomeric species and
appropriate solvent controls, media was removed and 100 µl of culture
media with 10 µg/ml resazurin was incubated with the cells for 2 h.
Fluorescence (Ex530nm/Em590nm) was measured on a CLARIOstar® plate
reader (BMG LABTECH, Buckinghamshire, UK). Culture media was
incubated with resazurin in parallel as a blank control. As a positive control,
cells were incubated with 1% (v/v) Triton X-100. Cell viability was
calculated as a percentage of live cells normalised to negative controls minus
relative fluorescence intensity (RFU) of blank wells. For LDH assay, the
Pierce LDH Cytotoxicity Assay Kit was used according to the
manufacturer’s instructions (cat. no. 88953; ThermoFisher Scientific).
Briefly, 50 µl of medium from each well was transferred to a 96-well plate,
followed by addition of 50 µl of reaction mixture, and incubated for 30 min
at room temperature in the dark. Cell culture media was included in parallel
as a blank control. After addition of 50 µl stop solution, absorbance
measurements at 490 nm and 680 nm were recorded on a CLARIOstar®
plate reader (BMG LABTECH). The A680nm (background signal from the
instrument) was subtracted from the A490nm followed by subtraction of
blanks. Percentages of live cells were determined by normalisation of the
absorbance values from the test sample to positive controls.
Statistical analysis
Statistical analysis was undertaken using StatsDirect version 3.0.126. Data
was unpaired and determined to be non-parametric following the Shapiro–
Wilk test of normality; therefore, a Kruskal–Wallis test was undertaken with
post hoc analysis. Post hoc analysis was only undertaken if the initial
significance test was at P<0.05. Dwass-Steel-Chritchlow-Fligner was used
for data points >6 and Conover-Inman post hoc analysis for <6 data points.
P-values are denoted on the graphs. Results of all statistical analysis
performed are shown in Table S1.
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Forster, J. I., Köglsberger, S., Trefois, C., Boyd, O., Baumuratov, A. S., Buck, L.,
Balling, R. and Antony, P. M. A. (2015). Characterization of differentiated SH-
SY5Y as neuronal screening model reveals increased oxidative vulnerability.
J. Biomol. Screen. 21, 496-509. doi:10.1177/1087057115625190
Goedert, M., Spillantini, M. G., Del Tredici, K. and Braak, H. (2013). 100 years of
Lewy pathology. Nat. Rev. Neurol. 9, 13-24. doi:10.1038/nrneurol.2012.242
Goldie, B. J., Barnett, M. M. and Cairns, M. J. (2014). BDNF and the maturation of
posttranscriptional regulatory networks in human SH-SY5Y neuroblast
differentiation. Front. Cell. Neurosci. 8, 1-7. doi:10.3389/fncel.2014.00325
Griffith, L. G. and Swartz, M. A. (2006). Capturing complex 3D tissue physiology in
vitro. Nat. Rev. Mol. Cell Biol. 7, 211-224. doi:10.1038/nrm1858
Hawkes, C. H., Del Tredici, K. and Braak, H. (2007). Parkinson’s disease: a dual-
hit hypothesis. Neuropathol. Appl. Neurobiol. 33, 599-614. doi:10.1111/j.1365-
2990.2007.00874.x
Illes-Toth, E., Ramos, M. R., Cappai, R., Dalton, C. and Smith, D. P. (2015).
Distinct higher-order α-synuclein oligomers induce intracellular aggregation.
Biochem. J. 468, 485-493. doi:10.1042/BJ20150159
Ioannidis, J. P. A. (2012). Extrapolating from animals to humans. Sci. Transl. Med.
4, 151ps15. doi:10.1126/scitranslmed.3004631
Ito, K., Eguchi, Y., Imagawa, Y., Akai, S., Mochizuki, H. and Tsujimoto, Y. (2017).
MPP+ induces necrostatin-1- and ferrostatin-1-sensitive necrotic death of neuronal
SH-SY5Y cells. Cell Death Discov. 3, 17013. doi:10.1038/cddiscovery.2017.13
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H. A.,
Kittel, A. and Saitoh, T. (1995). The precursor protein of non-Aβ component of
Alzheimer’s disease amyloid is a presynaptic protein of the central nervous
system. Neuron 14, 467-475. doi:10.1016/0896-6273(95)90302-X
Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Schindzielorz,
A., Okochi, M., Leimer, U., van Der Putten, H., Probst, A. et al. (2000).
Subcellular localization of wild-type and Parkinson’s disease-associated mutant
alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 20,
6365-6373. doi:10.1523/JNEUROSCI.20-17-06365.2000
Koprich, J. B., Kalia, L. V. and Brotchie, J. M. (2017). Animal models of α-
synucleinopathy for Parkinson disease drug development.Nat. Rev. Neurosci. 18,
515-529. doi:10.1038/nrn.2017.75
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. andOlanow, C.W. (2008).
Lewy body–like pathology in long-term embryonic nigral transplants in
Parkinson’s disease. Nat. Med. 14, 504-506. doi:10.1038/nm1747
Korecka, J. A., Van Kesteren, R. E., Blaas, E., Spitzer, S. O., Kamstra, J. H.,
Smit, A. B., Swaab, D. F., Verhaagen, J. and Bossers, K. (2013). Phenotypic
characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional
profiling. PLoS ONE 8, e63862. doi:10.1371/journal.pone.0063862
Kovalevich, J. and Langford, D. (2013). Considerations for the use of SH-SY5Y
neuroblastoma cells in neurobiology.Methods Mol. Biol. 1078, 9-21. doi:10.1007/
978-1-62703-640-5_2
Krishna, A., Biryukov, M., Trefois, C., Antony, P. M. A., Hussong, R., Lin, J.,
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